Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol

Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol

Abstract Background Each year, 45,000 women worldwide develop vulvar cancer, often occurred from vulvar high-grade squamous intraepithelial lesions (vHSIL), a precancerous stage associated with high- risk human papillomavirus (HPV). Recurrent vHSIL, experienced by over 30% of patients despite treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Vera J. G. M. Vaessen, Ralf L. O. van de Laar, Marta Piso-Jozwiak, Virgil A. S. H. Dalm, Elmar A. Joura, Matthias Jentschke, Heleen J. van Beekhuizen
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Vulvar neoplasms
Vulvar high-grade squamous intraepithelial lesion
Papillomavirus vaccines
Adjuvant HPV vaccination
Vulvar HSIL treatment
Vulvar cancer
Online Access:https://doi.org/10.1186/s12885-025-14275-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14275-w

Similar Items